Dario Ferrero

3.8k total citations
92 papers, 2.0k citations indexed

About

Dario Ferrero is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Dario Ferrero has authored 92 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hematology, 28 papers in Genetics and 27 papers in Molecular Biology. Recurrent topics in Dario Ferrero's work include Acute Myeloid Leukemia Research (40 papers), Hematopoietic Stem Cell Transplantation (18 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Dario Ferrero is often cited by papers focused on Acute Myeloid Leukemia Research (40 papers), Hematopoietic Stem Cell Transplantation (18 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Dario Ferrero collaborates with scholars based in Italy, United States and Germany. Dario Ferrero's co-authors include Corrado Tarella, Eugenio Gallo, Riccardo Dalla‐Favera, G Rovera, Francis W. Ruscetti, Alessandro Pileri, Giovanni Luca Pagliardi, Stephanie Seremetis, Silvana Pessano and Lisabianca Bottero and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Dario Ferrero

90 papers receiving 1.9k citations

Peers

Countries citing papers authored by Dario Ferrero

Since Specialization

Citations

This map shows the geographic impact of Dario Ferrero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dario Ferrero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dario Ferrero more than expected).

Fields of papers citing papers by Dario Ferrero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dario Ferrero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dario Ferrero. The network helps show where Dario Ferrero may publish in the future.

Co-authorship network of co-authors of Dario Ferrero

This figure shows the co-authorship network connecting the top 25 collaborators of Dario Ferrero. A scholar is included among the top collaborators of Dario Ferrero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dario Ferrero. Dario Ferrero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes 2025 ·Frontiers in Immunology ·Alberto Mella, (unknown), Valeria Deiana, (unknown), (unknown), Ester Gallo, (unknown), (unknown), (unknown), Fabrizio Fop, (unknown), Federica Cavallo, (unknown), Dario Ferrero, Roberto Mina, Corrado Tarella, Benedetto Bruno, Filippo Mariano, (unknown)	1
2	Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission 2024 ·Blood Advances ·(unknown), Étienne Lengliné, Florence Rabian, Marco Cerrano, Rathana Kim, (unknown), Dario Ferrero, Marie Sébert, Nathalie Dhédin, Raphaël Itzykson, Lionel Adès, Emmanuel Raffoux, Hervé Dombret, Ernesta Audisio, Emmanuelle Clappier, Nicolas Boissel	2
3	Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience 2023 ·Leukemia Research ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Stefano D’Ardìa, Chiara Frairia, Valentina Giai, Roberto Freilone, Benedetto Bruno, (unknown), Luisa Giaccone, Alessandro Busca, Chiara Maria Dellacasa, Dario Ferrero, Ernesta Audisio, Marco Cerrano	1
4	Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges 2023 ·Current Treatment Options in Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Roberto Freilone, Benedetto Bruno, Ernesta Audisio, Dario Ferrero, Eloise Beggiato, Marco Cerrano	7
5	Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors 2023 ·Cancers ·(unknown), (unknown), (unknown), Giulia Arrigo, (unknown), (unknown), Stefano D’Ardìa, Chiara Frairia, Valentina Giai, Roberto Freilone, Dario Ferrero, Ernesta Audisio, Marco Cerrano	16
6	Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study 2022 ·Annals of Hematology ·(unknown), Marco Cerrano, Daniela Di Cuonzo, (unknown), (unknown), (unknown), Stefano D’Ardìa, Chiara Frairia, Valentina Giai, (unknown), (unknown), Roberto Freilone, Luisa Giaccone, Alessandro Busca, Chiara Maria Dellacasa, Ernesta Audisio, Dario Ferrero, Eloise Beggiato	29
7	DROPLED DIGITAL PCR MAY HAVE A PROGNOSTIC VALUE FOR PREDICTING RELAPSE AFTER IMATINIB DISCONTINUATION 2016 ·Haematologica ·Carmen Fava, (unknown), Paola Berchialla, Enrico Gottardi, Filomena Daraio, (unknown), Emilia Giugliano, (unknown), (unknown), Daniele Cattaneo, Ester Orlandi, (unknown), Patrizia Pregno, (unknown), Dario Ferrero, (unknown), Giovanna Rege‐Cambrin, Giuseppe Saglio	0
8	IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE 2015 ·Haematologica ·(unknown), Carmen Fava, Irene Dogliotti, Paola Berchialla, (unknown), Marco Cerrano, Dario Ferrero, Maura Nicolosi, Patrizia Pregno, Ester Orlandi, Daniele Cattaneo, Alessandra Iurlo, Gianluca Catania, (unknown), Giuseppe Saglio	1
9	Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents 2014 ·Annals of Hematology ·Dario Ferrero, Elena Crisà, Filippo Marmont, Ernesta Audisio, Chiara Frairia, Valentina Giai, (unknown), Moreno Festuccia, Benedetto Bruno, Ludovica Riera, Roberto Passera, Mario Boccadoro	20
10	A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs 2010 ·Annals of Hematology ·Elena Crisà, (unknown), Roberto Passera, Matthew Prina, Piercarla Schinco, (unknown), Valentina Giai, (unknown), Mario Bazzan, A Vaccarino, Mario Boccadoro, Dario Ferrero	39
11	Increase of telomerase activity and hTERT expression in myelodysplastic syndromes 2009 ·Cancer Biology & Therapy ·Federica Briatore, Giuseppina Barrera, Stefania Pizzimenti, Cristina Toaldo, (unknown), Stefano Laurora, Piergiorgio Pettazzoni, Umberto Dianzani, Dario Ferrero	36
12	Growth advantage of chronic myeloid leukemia CFU-GM in vitro : survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids ± α-interferon 2001 ·Leukemia ·Dario Ferrero, (unknown), (unknown), (unknown), (unknown), Alessandro Pileri	6
13	A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation 1998 ·Bone Marrow Transplantation ·Dario Ferrero, Corrado Tarella, (unknown), P Bondesan, Paola Omedè, (unknown), Daniele Caracciolo, Claudia Castellino, Alessandro Pileri	9
14	Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: Modulating effects of dihydroxylated vitamin D3, α interferon and ‘stem cell factor’ 1997 ·Leukemia Research ·Dario Ferrero, Nadia Carlesso, (unknown), (unknown), Patrizia Pregno, Eugenio Gallo, Alessandro Pileri	8
15	Harlequin granulocyte-colony stimulating factor interleukin 6 molecules with bifunctional and antagonistic activities 1997 ·Immunotechnology ·Maria Grazia Cusi, Dario Ferrero	1
16	Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF 1991 ·European Journal of Cancer and Clinical Oncology ·Corrado Tarella, Dario Ferrero, Marco Bregni, Salvatore Siena, Eugenio Gallo, Alessandro Pileri, Alessandro M. Gianni	67
17	Ras oncogene mutation in multiple myeloma. 1989 ·The Journal of Experimental Medicine ·Antonino Neri, James P. Murphy, Lilla Cro, Dario Ferrero, Corrado Tarella, Luca Baldini, Riccardo Dalla‐Favera	145
18	Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. 1989 ·Leukemia Research ·Paolo de Fabritiis, Dario Ferrero, (unknown), Corrado Tarella, G Meloni, Alessandro Pulsoni, Patrizia Pregno, (unknown), Lidia De Felice, (unknown), Sergio Amadori, Franco Mandelli, Alessandro Pileri	6
19	Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. 1989 ·PubMed ·Paolo de Fabritiis, Dario Ferrero, (unknown), Corrado Tarella, G Meloni, Alessandro Pulsoni, Patrizia Pregno, (unknown), Lidia De Felice, Eugenio Gallo	23
20	Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation. 1982 ·PubMed ·Dario Ferrero, Corrado Tarella, Eugenio Gallo, Francis W. Ruscetti, Theodore R. Breitman	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact